Cargando…

Interleukin-6 is elevated in synovial fluid of patients with focal cartilage defects and stimulates cartilage matrix production in an in vitro regeneration model

INTRODUCTION: This study aimed to determine whether, as in osteoarthritis, increased levels of interleukin-6 (IL-6) are present in the synovial fluid of patients with symptomatic cartilage defects and whether this IL-6 affects cartilage regeneration as well as the cartilage in the degenerated knee....

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuchida, Anika I, Beekhuizen, Michiel, Rutgers, Marijn, van Osch, Gerjo JVM, Bekkers, Joris EJ, Bot, Arjan GJ, Geurts, Bernd, Dhert, Wouter JA, Saris, Daniel BF, Creemers, Laura B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674617/
https://www.ncbi.nlm.nih.gov/pubmed/23206933
http://dx.doi.org/10.1186/ar4107
_version_ 1782272392693809152
author Tsuchida, Anika I
Beekhuizen, Michiel
Rutgers, Marijn
van Osch, Gerjo JVM
Bekkers, Joris EJ
Bot, Arjan GJ
Geurts, Bernd
Dhert, Wouter JA
Saris, Daniel BF
Creemers, Laura B
author_facet Tsuchida, Anika I
Beekhuizen, Michiel
Rutgers, Marijn
van Osch, Gerjo JVM
Bekkers, Joris EJ
Bot, Arjan GJ
Geurts, Bernd
Dhert, Wouter JA
Saris, Daniel BF
Creemers, Laura B
author_sort Tsuchida, Anika I
collection PubMed
description INTRODUCTION: This study aimed to determine whether, as in osteoarthritis, increased levels of interleukin-6 (IL-6) are present in the synovial fluid of patients with symptomatic cartilage defects and whether this IL-6 affects cartilage regeneration as well as the cartilage in the degenerated knee. METHODS: IL-6 concentrations were determined by ELISA in synovial fluid and in conditioned media of chondrocytes regenerating cartilage. Chondrocytes were obtained from donors with symptomatic cartilage defects, healthy and osteoarthritic donors. The effect of IL-6 on cartilage regeneration and on metabolism of the resident cartilage in the knee was studied by both inhibition of endogenous IL-6 and addition of IL-6, in a regeneration model and in osteoarthritic explants in the presence of synovial fluid, respectively. Readout parameters were DNA and glycosaminoglycan (GAG) content and release. Differences between controls and IL-6 blocked or supplemented samples were determined by univariate analysis of variance using a randomized block design. RESULTS: Synovial fluid of patients with symptomatic cartilage defects contained more IL-6 than synovial fluid of healthy donors (P = 0.001) and did not differ from osteoarthritic donors. IL-6 production of osteoarthritic chondrocytes during cartilage regeneration was higher than that of healthy and defect chondrocytes (P < 0.001). Adding IL-6 increased GAG production by healthy chondrocytes and decreased GAG release by osteoarthritic chondrocytes (P < 0.05). Inhibition of IL-6 present in osteoarthritic synovial fluid showed a trend towards decreased GAG content of the explants (P = 0.06). CONCLUSIONS: Our results support a modest anabolic role for IL-6 in cartilage matrix production. Targeting multiple cytokines, including IL-6, may be effective in improving cartilage repair in symptomatic cartilage defects and osteoarthritis.
format Online
Article
Text
id pubmed-3674617
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36746172013-06-10 Interleukin-6 is elevated in synovial fluid of patients with focal cartilage defects and stimulates cartilage matrix production in an in vitro regeneration model Tsuchida, Anika I Beekhuizen, Michiel Rutgers, Marijn van Osch, Gerjo JVM Bekkers, Joris EJ Bot, Arjan GJ Geurts, Bernd Dhert, Wouter JA Saris, Daniel BF Creemers, Laura B Arthritis Res Ther Research Article INTRODUCTION: This study aimed to determine whether, as in osteoarthritis, increased levels of interleukin-6 (IL-6) are present in the synovial fluid of patients with symptomatic cartilage defects and whether this IL-6 affects cartilage regeneration as well as the cartilage in the degenerated knee. METHODS: IL-6 concentrations were determined by ELISA in synovial fluid and in conditioned media of chondrocytes regenerating cartilage. Chondrocytes were obtained from donors with symptomatic cartilage defects, healthy and osteoarthritic donors. The effect of IL-6 on cartilage regeneration and on metabolism of the resident cartilage in the knee was studied by both inhibition of endogenous IL-6 and addition of IL-6, in a regeneration model and in osteoarthritic explants in the presence of synovial fluid, respectively. Readout parameters were DNA and glycosaminoglycan (GAG) content and release. Differences between controls and IL-6 blocked or supplemented samples were determined by univariate analysis of variance using a randomized block design. RESULTS: Synovial fluid of patients with symptomatic cartilage defects contained more IL-6 than synovial fluid of healthy donors (P = 0.001) and did not differ from osteoarthritic donors. IL-6 production of osteoarthritic chondrocytes during cartilage regeneration was higher than that of healthy and defect chondrocytes (P < 0.001). Adding IL-6 increased GAG production by healthy chondrocytes and decreased GAG release by osteoarthritic chondrocytes (P < 0.05). Inhibition of IL-6 present in osteoarthritic synovial fluid showed a trend towards decreased GAG content of the explants (P = 0.06). CONCLUSIONS: Our results support a modest anabolic role for IL-6 in cartilage matrix production. Targeting multiple cytokines, including IL-6, may be effective in improving cartilage repair in symptomatic cartilage defects and osteoarthritis. BioMed Central 2012 2012-12-03 /pmc/articles/PMC3674617/ /pubmed/23206933 http://dx.doi.org/10.1186/ar4107 Text en Copyright ©2012 Tsuchida et al.; licensee BioMed Central Ltd http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Tsuchida, Anika I
Beekhuizen, Michiel
Rutgers, Marijn
van Osch, Gerjo JVM
Bekkers, Joris EJ
Bot, Arjan GJ
Geurts, Bernd
Dhert, Wouter JA
Saris, Daniel BF
Creemers, Laura B
Interleukin-6 is elevated in synovial fluid of patients with focal cartilage defects and stimulates cartilage matrix production in an in vitro regeneration model
title Interleukin-6 is elevated in synovial fluid of patients with focal cartilage defects and stimulates cartilage matrix production in an in vitro regeneration model
title_full Interleukin-6 is elevated in synovial fluid of patients with focal cartilage defects and stimulates cartilage matrix production in an in vitro regeneration model
title_fullStr Interleukin-6 is elevated in synovial fluid of patients with focal cartilage defects and stimulates cartilage matrix production in an in vitro regeneration model
title_full_unstemmed Interleukin-6 is elevated in synovial fluid of patients with focal cartilage defects and stimulates cartilage matrix production in an in vitro regeneration model
title_short Interleukin-6 is elevated in synovial fluid of patients with focal cartilage defects and stimulates cartilage matrix production in an in vitro regeneration model
title_sort interleukin-6 is elevated in synovial fluid of patients with focal cartilage defects and stimulates cartilage matrix production in an in vitro regeneration model
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674617/
https://www.ncbi.nlm.nih.gov/pubmed/23206933
http://dx.doi.org/10.1186/ar4107
work_keys_str_mv AT tsuchidaanikai interleukin6iselevatedinsynovialfluidofpatientswithfocalcartilagedefectsandstimulatescartilagematrixproductioninaninvitroregenerationmodel
AT beekhuizenmichiel interleukin6iselevatedinsynovialfluidofpatientswithfocalcartilagedefectsandstimulatescartilagematrixproductioninaninvitroregenerationmodel
AT rutgersmarijn interleukin6iselevatedinsynovialfluidofpatientswithfocalcartilagedefectsandstimulatescartilagematrixproductioninaninvitroregenerationmodel
AT vanoschgerjojvm interleukin6iselevatedinsynovialfluidofpatientswithfocalcartilagedefectsandstimulatescartilagematrixproductioninaninvitroregenerationmodel
AT bekkersjorisej interleukin6iselevatedinsynovialfluidofpatientswithfocalcartilagedefectsandstimulatescartilagematrixproductioninaninvitroregenerationmodel
AT botarjangj interleukin6iselevatedinsynovialfluidofpatientswithfocalcartilagedefectsandstimulatescartilagematrixproductioninaninvitroregenerationmodel
AT geurtsbernd interleukin6iselevatedinsynovialfluidofpatientswithfocalcartilagedefectsandstimulatescartilagematrixproductioninaninvitroregenerationmodel
AT dhertwouterja interleukin6iselevatedinsynovialfluidofpatientswithfocalcartilagedefectsandstimulatescartilagematrixproductioninaninvitroregenerationmodel
AT sarisdanielbf interleukin6iselevatedinsynovialfluidofpatientswithfocalcartilagedefectsandstimulatescartilagematrixproductioninaninvitroregenerationmodel
AT creemerslaurab interleukin6iselevatedinsynovialfluidofpatientswithfocalcartilagedefectsandstimulatescartilagematrixproductioninaninvitroregenerationmodel